Biosolution Co Ltd
086820
Company Profile
Business description
Biosolution Co Ltd is a Korean company offering Cell-Based Biotechnology. It is engaged in manufacturing and selling cell therapy products, and developing cell therapeutics technology. Its main areas include cell-based therapeutics with their background in somatic and stem cell technology, and the manufacturing, sales, and R&D of human tissue models for screening toxicity and efficacy with tissue engineering technology.
Contact
Gongneung-Ro 232, Nowon-gu
5th Floor, Room 519, Seoul Technopark
Seoul
KORT: +82 234468884
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
88
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,040.10 | 87.10 | -0.95% |
| CAC 40 | 7,654.25 | 53.65 | -0.70% |
| DAX 40 | 23,487.33 | 550.00 | -2.29% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,116.69 | 79.65 | -0.87% |
| HKSE | 25,381.57 | 114.98 | -0.45% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 42,035.72 | 274.77 | -0.65% |
| NZX 50 Index | 13,049.69 | 83.47 | -0.64% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,768.10 | 90.90 | -1.03% |
| SSE Composite Index | 3,820.98 | 37.15 | -0.96% |